Effect of Simvastatin at Different Doses on Inflammatory Factors and Renal Function in Senile Patients with Diabetic Kidney Disease
- VernacularTitle:不同剂量辛伐他汀对老年早期糖尿病肾病患者炎症因子和肾功能的影响观察
- Author:
Shengmiao ZHANG
;
Xiaorong CHEN
- Publication Type:Journal Article
- Keywords:
Diabetic kidney disease;
Simvastatin;
Dose;
Inflammatory factors;
Renal function
- From:
China Pharmacist
2015;(11):1935-1937
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the effect of simvastatin at different doses on the inflammatory factors and renal function in se-nile patients with diabetic kidney disease ( DKD) . Methods:Totally 160 cases of DKD patients were randomly divided into the control group, low dose group, conventional dose group and high dose group. All the patients were given the foundation treatment, and the low dose group, conventional dose group and high dose group was respectively given simvastatin 10, 20,40 mg·d-1 . The changes of in-flammatory cytokines (CRP, ICAM-1 and IL-1β) and renal index (BUN, Cr, UAER, 24hUpro and Uβ2-MG) among the groups were observed and compared before and after the 4-week treatment. Results:CRP in the high dose group after the treatment was significantly decreased when compared with that before the treatment and that in the control group after the treatment, and the difference was statisti-cally significant (P<0. 05). ICAM-1 in the low dose group, conventional dose group and high dose group was significantly decreased when compared with that before the treatment and that in the control group after the treatment, and the difference was statistically sig-nificant (P<0. 05). IL-1β in the four groups after the treatment had no obvious change when compared with that before the treatment, and there was no significant difference among the groups (P >0.05). BUN in the four groups after the treatment had no obvious change when compared with that before the treatment, and there was no significant difference among the groups (P>0. 05). Cr and UAER in the four groups after the treatment were significantly decreased (P<0. 05), those in the low dose group, conventional dose group and high dose group after the treatment were significantly lower than those in the control group after the treatment (P<0. 05), and those in the conventional dose group and high dose group after the treatment were significantly lower than those in the low dose group after the treatment (P<0. 05). 24hUpro in the low dose group, conventional dose group and high dose group after the treatment was significantly decreased when compared with that before the treatment and that in the control group after the treatment (P<0. 05). Uβ2-MG in the low dose group, conventional dose group and high dose group after the treatment was significantly decreased when com-pared with that before the treatment and that in the control group after the treatment (P<0. 05), that in the conventional dose group and high dose group after the treatment was significantly decreased when compared with that in the low dose group after the treatment (P<0. 05), and that in the high dose group after the treatment was significantly lower than that in the conventional dose group after the treatment (P<0. 05). ③There was no statistically significant difference in the adverse reactions incidence among the four groups (P>0. 05). Conclusion:Simvastatin can improve diabetic nephropathy conditions in two aspects of inflammation factors and renal in-dex, and simvastatin at high dose shows more advantages.
